Catalyst Pharmaceuticals announces upcoming investor conference participation by CEO Richard J. Daly and management team.
Quiver AI Summary
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing treatments for rare diseases, announced that its President and CEO, Richard J. Daly, and the management team will participate in several investor conferences in early September 2025. The conferences include the Wells Fargo Healthcare Conference, the Cantor Global Healthcare Conference, the H.C. Wainwright 27th Annual Global Investment Conference, and the Baird Global Conference, with presentations scheduled at various times. Webcasts of these presentations will be available on the Company’s website for 30 days. Catalyst, based in Coral Gables, Florida, focuses on making innovative therapies accessible to patients and was recognized in 2025 for its growth and success. The release also includes forward-looking statements with known risks and uncertainties impacting future results.
Potential Positives
- Catalyst Pharmaceuticals will participate in multiple high-profile investor conferences, showcasing its commitment to transparency and engagement with the investment community.
- The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies, highlighting its strong market position and business performance.
- Catalyst's inclusion in the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies emphasizes its innovative capabilities and growth trajectory in the biopharmaceutical sector.
Potential Negatives
- Forward-looking statements included in the release indicate uncertainty about future performance, which could deter investor confidence.
- The press release mentions potential risks and uncertainties that may cause actual results to differ materially from expectations, highlighting vulnerability in the company’s forecasts.
- While Catalyst is recognized for its achievements, the focus on upcoming investor conferences could imply a need to rebuild or maintain investor interest amidst potential market challenges.
FAQ
What is Catalyst Pharmaceuticals focused on?
Catalyst Pharmaceuticals focuses on developing and commercializing novel medicines for rare and difficult-to-treat diseases.
When will Catalyst participate in upcoming investor conferences?
Catalyst will participate in investor conferences on September 3, 4, 8, and 9, 2025.
Where can I find the webcast links for the conferences?
The webcast links for the conferences are available in the Investors section on Catalyst's website.
How long will the conference replays be available?
The replays of the webcasts will be available for at least 30 days.
What accolades has Catalyst Pharmaceuticals received recently?
Catalyst was recognized as one of America's Most Successful Mid-Cap Companies by Forbes and one of North America's Fastest-Growing Companies by Deloitte.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CPRX Insider Trading Activity
$CPRX insiders have traded $CPRX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $CPRX stock by insiders over the last 6 months:
- GARY INGENITO (Chief Med. & Reg. Officer) has made 0 purchases and 4 sales selling 469,000 shares for an estimated $10,670,329.
- PATRICK J MCENANY has made 0 purchases and 2 sales selling 200,000 shares for an estimated $5,217,338.
- RICHARD J DALY (President and CEO) sold 70,000 shares for an estimated $1,740,200
- BRIAN ELSBERND (Chief Compliance/Legal Officer) has made 0 purchases and 2 sales selling 62,975 shares for an estimated $1,446,932.
- CARMEN JEFFREY DEL (Chief Commercial Officer) sold 30,423 shares for an estimated $696,382
- PREETHI SUNDARAM (Chief Strategy Officer) has made 0 purchases and 2 sales selling 3,924 shares for an estimated $103,648.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CPRX Hedge Fund Activity
We have seen 204 institutional investors add shares of $CPRX stock to their portfolio, and 195 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,879,476 shares (+inf%) to their portfolio in Q2 2025, for an estimated $62,484,629
- AMERICAN CENTURY COMPANIES INC added 1,231,419 shares (+233.9%) to their portfolio in Q2 2025, for an estimated $26,721,792
- MORGAN STANLEY added 788,968 shares (+32.9%) to their portfolio in Q2 2025, for an estimated $17,120,605
- GOLDMAN SACHS GROUP INC removed 723,813 shares (-23.1%) from their portfolio in Q2 2025, for an estimated $15,706,742
- FUNDSMITH LLP added 557,812 shares (+25.9%) to their portfolio in Q2 2025, for an estimated $12,104,520
- BANK OF AMERICA CORP /DE/ added 554,200 shares (+30.6%) to their portfolio in Q2 2025, for an estimated $12,026,140
- JANUS HENDERSON GROUP PLC added 431,733 shares (+135.0%) to their portfolio in Q2 2025, for an estimated $9,368,606
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CPRX Analyst Ratings
Wall Street analysts have issued reports on $CPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 03/03/2025
To track analyst ratings and price targets for $CPRX, check out Quiver Quantitative's $CPRX forecast page.
Full Release
CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.
2025 Wells Fargo Healthcare Conference
Date:
Wednesday, September 3, 2025
Presentation:
2:15 PM ET
Webcast Link
2025 Cantor Global Healthcare Conference
Date:
Thursday, September 4, 2025
Presentation:
3:20 PM ET
Webcast Link
H.C. Wainwright 27th Annual Global Investment Conference
Date:
Monday, September 8, 2025
Presentation:
9:00am ET
Webcast Link
Baird Global Conference
Date:
Tuesday, September 9, 2025
Presentation:
12:50pm ET
Webcast Link
The webcasts will be available under the Investors section on the Company's website, www.catalystpharma.com , and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com .
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
